度洛西汀治疗躯体化障碍的疗效评价

Evaluations of curative effects of duloxetine in the treatment of patients with somatization disorder

目的探讨度洛西汀治疗躯体化障碍的疗效。方法将82例躯体化障碍的患者进行为期6周治疗。采用SCL-90评定疗效,副反应量表(TESS)评定副反应,疗效评定以减分率及有效率为评定指标。结果口服度洛西汀6周后有效率为84.15%,较2周、4周末显著提高(P<0.01);治疗前躯体化障碍患者SCL-90总分及各项因子分明显高于国内常模,躯体化、焦虑、抑郁、偏执因子分升高明显,治疗后各因子分较治疗前显著降低(P<0.05),度洛西汀治疗副反应轻微。结论度洛西汀对躯体化障碍有较好疗效,而副反应较低。

Objective To study the effect of duloxetine in treatment of patients with somatization disorder. Methods Eighty-two patients with somatization disorder were treated with duloxetine 20 - 40 mg/d for weeks. The clinical effect and side effects was assessed by SCL-90 and TESS respectively. Results At the end of 6 weeks of treatment, the responsive rate was 84. 7%. All item scores of SCL-90 decreased（P 〈0.05） and its side effects were less. Conclusion Duloxetine is effective in the treatment of patients with somatization disorder and its side effects were less.